Computer predicts leukemia remission with 90% accuracy

Researchers have developed a computer learning algorithm capable of predicting remission rates for patient with acute myelogenous leukemia (AML).

Using bone marrow data and medical histories of patients with AML, the computer was trained to predict remission with 100 percent accuracy via predictive analytics. Incidents of relapse was predicted in 90 percent of cases.

"It's pretty straightforward to teach a computer to recognize AML, once you develop a robust algorithm, and in previous work we did it with almost 100 percent accuracy," said Murat Dundar, senior author of the disease-progression study and associate professor of computer science in the School of Science at Indiana University-Purdue University Indianapolis. "What was challenging was to go beyond that work and teach the computer to accurately predict the direction of change in disease progression in AML patients, interpreting new data to predict the unknown: which new AML patients will go into remission and which will relapse."

This high rate in accurate predictions give both patient and physician the chance to prepare for future treatments. The early start in knowing what works well for each individual patient means for higher quality care and creates clinical decision support.

"Machine learning is not about modeling data. It's about extracting knowledge from the data you have so you can build a powerful, intuitive tool that can make predictions about future data that the computer has not previously seen—the machine is learning, not memorizing—and that's what we did," said Dundar, an internationally respected machine-learning scientist who specializes in teaching computers to understand biomedical data.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.